Investment firm Wall Street Zen has upgraded Structure Therapeutics (NASDAQ: GPCR) from a “sell” to a “hold” rating, according to a report released on Saturday. This change reflects a broader reassessment of the company’s stock, which has attracted attention from various analysts recently.
Analyst Ratings and Price Targets
Several other financial institutions have also evaluated Structure Therapeutics’ stock. HC Wainwright reaffirmed a “buy” rating with a target price of $60.00 on November 28. In a separate report, Morgan Stanley increased their price target from $120.00 to $125.00, maintaining an “overweight” rating. Meanwhile, Stifel Nicolaus raised their price objective from $50.00 to $90.00, classifying the stock as a “buy” in a report published on December 8.
In contrast, Zacks Research downgraded Structure Therapeutics from a “hold” to a “strong sell” rating on October 17. Despite these mixed evaluations, Lifesci Capital recently upgraded the company to a “strong buy” rating on September 8. Overall, one analyst has given a “strong buy” rating, eleven have issued “buy” ratings, and two have recommended selling the stock. Currently, the average rating stands at “moderate buy” with an average target price of $95.78, based on data from MarketBeat.
Recent Financial Performance
Structure Therapeutics reported its quarterly earnings on November 6, revealing a loss of $0.37 per share. This figure fell short of the consensus estimate of $0.36 by $0.01. Analysts anticipate that the company will report earnings of -$0.82 per share for the current fiscal year, highlighting ongoing challenges in its financial performance.
Institutional Investment Trends
Institutional investors have been actively adjusting their stakes in Structure Therapeutics. The State of Wyoming acquired a new stake valued at approximately $28,000 in the second quarter. Additionally, EverSource Wealth Advisors LLC significantly increased its holdings by 530.0% in the third quarter, now owning 1,071 shares valued at $30,000 after adding 901 shares recently.
Other noteworthy changes include National Bank of Canada FI, which raised its position by 1,448.2% in the first quarter, now holding 2,957 shares worth $51,000, and Assetmark Inc. that boosted its stake by 39.9% during the second quarter, owning 2,877 shares valued at $60,000 after acquiring an additional 820 shares. Overall, approximately 91.78% of the stock is currently owned by hedge funds and institutional investors.
About Structure Therapeutics
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company focused on developing innovative oral therapeutics aimed at addressing a variety of chronic diseases with unmet medical needs. Its lead product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like peptide-1 receptor, which is a recognized therapeutic target for type-2 diabetes and obesity.
This recent upgrade and the accompanying analysis point to a complex landscape for investors considering Structure Therapeutics, as multiple ratings reflect varied perspectives on its potential moving forward.
